CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞相关毒性的管理：学习曲线迄今教会我们什么
英文原题：Management of CAR T-cell Related Toxicities: What did the Learning Curve Teach us so Far?
查看英文原题
Management of CAR T-cell Related Toxicities: What did the Learning Curve Teach us so Far?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法是一种免疫疗法，代表了B细胞恶性肿瘤和多发性骨髓瘤治疗领域的治疗突破。自2017年首个CAR-T 细胞获批以来，已有五个FDA批准的CAR-T 产品，更多CAR-T 疗法的适应症获批，以及针对其他癌症（包括实体器官恶性肿瘤）的研究性试验启动。CAR-T 疗法具有独特的毒性。随着时间推移，对这些毒性的更深入了解有助于更高效的诊断、管理和治疗策略。本综述将聚焦于CAR-T 相关毒性，包括细胞因子释放综合征、免疫效应细胞相关神经毒性综合征（ICANS）、细胞因子释放综合征（CRS）以及噬血细胞性淋巴组织细胞增生症（HLH）/巨噬细胞活化综合征，从评估、分级和当前管理策略方面进行讨论。此外，本综述将涵盖CAR-T 相关毒性的未来方向和研究。
展开英文摘要原文
Chimeric antigen receptor T cell (CAR-T) therapy is an immunotherapy, which represents a therapeutic breakthrough in the treatment of B-cell malignancies and multiple myeloma. Since the first CAR T-cell approval in 2017, there have been five FDA approved CAR-T products, more approved disease indications for CAR-T therapy, and investigational trials launched for other cancers, including solid organ malignancies. CAR-T therapy possesses unique toxicities.
Better understanding of these toxicities over time has helped in more efficient diagnosis, management, and treatment strategies. This review will focus on CAR-T-related toxicities including cytokine release syndrome, immune effector cell associated neurotoxicity syndrome (ICANS), cytokine release syndrome (CRS), and hemophagocytic lymphohistiocytosis (HLH)/ macrophage activation syndrome in terms of assessment, grading, and current management strategies.
Additionally, this review will cover future directions and research on CAR-T-related toxicities.
论文信息
- 作者
- Murthy HS、Yassine F、Iqbal M、Alotaibi S、Moustafa MA、Kharfan-Dabaja MA
- 单位
- Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Programs, Mayo Clinic, Jacksonville, FL, USA.United States
- 文献类型
- 综述
- 期刊
- Hematology/oncology and stem cell therapy2022 Nov 7
- 原文标识
- PubMed 36395496 · DOI 10.56875/2589-0646.1029